Related Experiment Video
Updated: Mar 28, 2026

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Regression of massive cardiac rhabdomyoma on everolimus therapy
Steven G Hoshal1, Bennett P Samuel2, Jeffrey R Schneider2
1College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.
Abstract:
Cardiac rhabdomyoma is the primary feature of the genetic disease, tuberous sclerosis complex, the most common cardiac tumor diagnosed in neonates and infants. Spontaneous regression is observed in most cases, but these tumors may cause hemodynamic instability, arrhythmias or other complications. We describe the case of a critically ill neonate, resuscitated after cardiac arrest secondary to massive locally invasive cardiac rhabdomyoma, who was successfully treated with everolimus (mammalian target of rapamycin [mTOR] inhibitor). Rapid tumor regression was observed on echocardiography, but it was unlikely that it was confounded by the natural disease course of regression. The presented case suggests that mTOR inhibitors may play a significant role in the treatment of large cardiac rhabdomyomas in critically ill neonates.
More Related Videos
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Mitral Stenosis III: Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy